A systematic review of economic evaluations of tyrosine kinase inhibitors of vascular endothelial growth factor receptors, mammalian target of rapamycin inhibitors and programmed death-1 inhibitors in metastatic renal cell cancer

ABSTRACT

Introduction: The therapeutic categories of tyrosine kinase inhibitors of vascular endothelial growth factor receptors, mammalian target of rapamycin inhibitors and programmed death-1 inhibitors have transformed the treatment of metastatic renal cell cancer. Nevertheless, this comes at an increased cost, in tandem with similar fiscal pressures in the broader oncology sector, which may jeopardize the sustainability of health systems.

Areas covered: To this direction, the economic evaluation of these agents is essential for rational and efficient decision-making and resource allocation process. The aim of this study is to glean, assess and present an outline of the available cost-effectiveness studies of these agents in the management of metastatic renal cell cancer.

Expert Commentary: We concluded that the results of the economic evaluations are pertinent, apart from the product under evaluation, to the country setting as well.

KEYWORDS:

• Mammalian target of rapamycin
• tyrosine kinase inhibitors of vascular endothelial growth factor receptors
• programmed death-1 inhibitors
• metastatic renal cell cancer
• systematic review of economic evaluations

Declaration of Interest

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. A reviewer on this manuscript has disclosed advisor and research grants for Novartis, EUSA, BMS and being a speaker for Novartis.

Additional information

Funding

This paper was not funded.